Currently, there is no curative treatment for Lesch-Nyhan disease (LND). Supportive treatment options depend on the phenotype, which includes overproduction of uric acid and its complications, as well as varying degrees of extrapyramidal and pyramidal signs, behavioral abnormalities including self-injurious behavior, and miscellaneous aspects such as macrocytic anemia.
Hyperuricemia
All patients have hyperuricemia. Allopurinol inhibits the conversion of xanthine and hypoxanthine to uric acid, and so reduces the risk of hyperuricemia-associated urologic and articular complications by effectively reducing serum acid levels.[37]Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007 Sep;56(9):1179-86.
http://www.ncbi.nlm.nih.gov/pubmed/17697859?tool=bestpractice.com
[38]Sweetman L, Nyhan WL. Excretion of hypoxanthine and xanthine in a genetic disease of purine metabolism. Nature. 1967 Aug 19;215(5103):859-60.
http://www.ncbi.nlm.nih.gov/pubmed/6049739?tool=bestpractice.com
Doses are titrated to maintain uric acid levels in the high-normal range and must be adjusted for renal insufficiency. In addition, generous hydration at all times is essential to wash out the oxypurines hypoxanthine and xanthine, and the allopurinol metabolite oxypurinol, which may also cause (radiolucent) renal stones.[39]Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol. 1985 Apr;133(4):658-9.
http://www.ncbi.nlm.nih.gov/pubmed/3981718?tool=bestpractice.com
[40]Morton WJ. Lesch-Nyhan syndrome. Urology. 1982 Nov;20(5):506-9.
http://www.ncbi.nlm.nih.gov/pubmed/7147530?tool=bestpractice.com
Renal stones
Renal stones, identified by renal colic, urinary obstruction, or routine ultrasound follow-up, require appropriate treatment in order to prevent long-term renal complications.[40]Morton WJ. Lesch-Nyhan syndrome. Urology. 1982 Nov;20(5):506-9.
http://www.ncbi.nlm.nih.gov/pubmed/7147530?tool=bestpractice.com
[41]Morino M, Shiigai N, Kusuyama H, et al. Extracorporeal shock wave lithotripsy and xanthine calculi in Lesch-Nyhan syndrome. Pediatr Radiol. 1992;22(4):304.
http://www.ncbi.nlm.nih.gov/pubmed/1523062?tool=bestpractice.com
Kidney stones in allopurinol-treated LND patients may contain uric acid, the oxypurines xanthine and hypoxanthine, or the allopurinol metabolite oxypurinol.[39]Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol. 1985 Apr;133(4):658-9.
http://www.ncbi.nlm.nih.gov/pubmed/3981718?tool=bestpractice.com
These stones are radiolucent, so renal ultrasound is the preferred modality for diagnosis.[40]Morton WJ. Lesch-Nyhan syndrome. Urology. 1982 Nov;20(5):506-9.
http://www.ncbi.nlm.nih.gov/pubmed/7147530?tool=bestpractice.com
Small urate stones can usually be managed by increasing fluid intake and by urine alkalinization, with potassium citrate being the preferred agent. Large stones and oxypurine stones may require lithotripsy or surgery, although the latter are more difficult to eliminate.[39]Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol. 1985 Apr;133(4):658-9.
http://www.ncbi.nlm.nih.gov/pubmed/3981718?tool=bestpractice.com
[41]Morino M, Shiigai N, Kusuyama H, et al. Extracorporeal shock wave lithotripsy and xanthine calculi in Lesch-Nyhan syndrome. Pediatr Radiol. 1992;22(4):304.
http://www.ncbi.nlm.nih.gov/pubmed/1523062?tool=bestpractice.com
Dystonia, chorea and ballismus
Extrapyramidal features in LND are mostly resistant to currently available therapies.
Various drug therapies have been tried. Dopaminergic drugs such as levodopa have inconsistent effects on the motor disorder and have been reported to worsen the condition.[21]Visser JE, Schretlen DJ, Bloem BR, Jinnah HA. Levodopa is not a useful treatment for Lesch-Nyhan disease. Mov Disord. 2011 Mar;26(4):746-9.
http://www.ncbi.nlm.nih.gov/pubmed/21506156?tool=bestpractice.com
[26]Watts RW, Spellacy E, Gibbs DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 1982;51(201):43-78.
http://www.ncbi.nlm.nih.gov/pubmed/7111674?tool=bestpractice.com
[42]Jankovic J, Caskey TC, Stout JT, et al. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May;23(5):466-9.
http://www.ncbi.nlm.nih.gov/pubmed/2455472?tool=bestpractice.com
Early treatment with levodopa/carbidopa (i.e., starting <1 year after the onset of symptoms) has been reported to improve the movement disorder in one patient but confirmative studies are warranted.[43]Serrano M, Perez-Duenas B, Ormazabal A, et al. Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks. Mov Disord. 2008 Jul 15;23(9):1297-300.
http://www.ncbi.nlm.nih.gov/pubmed/18528895?tool=bestpractice.com
Symptomatic treatment of severe dystonia (e.g., to improve hand function or prevent contractures) can be performed by botulinum toxin injections in selected muscles. Choreiform and ballistic movements do not consistently improve with a dopamine receptor antagonist (e.g., fluphenazine, pimozide) or drugs that deplete dopamine stores (tetrabenazine).[26]Watts RW, Spellacy E, Gibbs DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 1982;51(201):43-78.
http://www.ncbi.nlm.nih.gov/pubmed/7111674?tool=bestpractice.com
[42]Jankovic J, Caskey TC, Stout JT, et al. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May;23(5):466-9.
http://www.ncbi.nlm.nih.gov/pubmed/2455472?tool=bestpractice.com
[44]Goldstein M, Anderson LT, Reuben R, et al. Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation. Lancet. 1985 Feb 9;1(8424):338-9.
http://www.ncbi.nlm.nih.gov/pubmed/2857386?tool=bestpractice.com
[45]Watts RW, McKeran RO, Brown E, et al. Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome. Arch Dis Child. 1974 Sep;49(9):693-702.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1649025/pdf/archdisch00849-0029.pdf
http://www.ncbi.nlm.nih.gov/pubmed/4472817?tool=bestpractice.com
Detailed reports on the use of trihexyphenidyl in LND are lacking.
Physical therapy is generally useful to prevent contractures and preserve overall physical condition.
Pyramidal signs
Muscle relaxants such as baclofen and dantrolene can be used to manage spasticity.[3]Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001:2537-2570.
Alternatively, benzodiazepines (e.g., diazepam) may be used. Benzodiazepines have the added advantage of reducing anxiety, which is known to exacerbate the extrapyramidal and behavioral features.
Often, a muscle relaxant and a benzodiazepine are used concurrently.
In addition, physical therapy may prevent contractures and preserve overall condition.
Behavioral abnormalities
No pharmacologic treatment has consistently demonstrated effectiveness in managing the behavioral disturbances in LND, including medications that influence dopamine and serotonin metabolism.[26]Watts RW, Spellacy E, Gibbs DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 1982;51(201):43-78.
http://www.ncbi.nlm.nih.gov/pubmed/7111674?tool=bestpractice.com
[44]Goldstein M, Anderson LT, Reuben R, et al. Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation. Lancet. 1985 Feb 9;1(8424):338-9.
http://www.ncbi.nlm.nih.gov/pubmed/2857386?tool=bestpractice.com
[45]Watts RW, McKeran RO, Brown E, et al. Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome. Arch Dis Child. 1974 Sep;49(9):693-702.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1649025/pdf/archdisch00849-0029.pdf
http://www.ncbi.nlm.nih.gov/pubmed/4472817?tool=bestpractice.com
[46]Anderson LT, Herrmann L, Dancis J. The effect of L-5-hydroxytryptophan on self-mutilation in Lesch-Nyhan disease: a negative report. Neuropadiatrie. 1976 Nov;7(4):439-42.
http://www.ncbi.nlm.nih.gov/pubmed/1087383?tool=bestpractice.com
No pharmacologic treatment has been reported as consistently reducing self-injurious behavior.[3]Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001:2537-2570. A positive effect of S-adenosylmethionine on behavior has not been established, as results are inconsistent.[47]Dolcetta D, Parmigiani P, Salmaso L, et al. Quantitative evaluation of the clinical effects of S-adenosylmethionine on mood and behavior in Lesch-Nyhan patients. Nucleosides Nucleotides Nucleic Acids. 2013;32(4):174-88.
http://www.ncbi.nlm.nih.gov/pubmed/24001191?tool=bestpractice.com
Behavioral abnormalities do not respond consistently to formal psychological treatment either.[3]Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001:2537-2570. Negative reinforcement usually increases unwanted behaviors, including self-injury.[48]Anderson L, Dancis J, Alpert M, et al. Punishment learning and self-mutilation in Lesch-Nyhan disease. Nature. 1977 Feb 3;265(5593):461-3.
http://www.ncbi.nlm.nih.gov/pubmed/834300?tool=bestpractice.com
[49]Bull M, LaVecchio F. Behavior therapy for a child with Lesch-Nyhan syndrome. Dev Med Child Neurol. 1978 Jun;20(3):368-75.
http://www.ncbi.nlm.nih.gov/pubmed/669067?tool=bestpractice.com
The most effective method of dealing with difficult behaviors is to acknowledge the fact that they are beyond the patient's control, engage the patient in an active environment, provide positive reinforcement for desired behaviors, and actively ignore undesirable behaviors. For many patients, it is of utmost importance that they feel understood.
Most LND patients need some form of physical restraint, such as arm splints, limb straps, or protective gloves.[3]Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001:2537-2570.[50]Ball TS, Datta PC, Rios M, et al. Flexible arm splints in the control of a Lesch-Nyhan victim's finger biting and a profoundly retarded client's finger sucking. J Autism Dev Disord. 1985 Jun;15(2):177-84.
http://www.ncbi.nlm.nih.gov/pubmed/3997744?tool=bestpractice.com
[51]Nyhan WL. Behavior in the Lesch-Nyhan syndrome. J Autism Child Schizophr. 1976 Sep;6(3):235-52.
http://www.ncbi.nlm.nih.gov/pubmed/1086851?tool=bestpractice.com
For biting, teeth extraction may be needed when conservative measures fail.[52]Cusumano FJ, Penna KJ, Panossian G. Prevention of self-mutilation in patients with Lesch-Nyhan syndrome: review of literature. ASDC J Dent Child. 2001 May-Jun;68(3):175-8.
http://www.ncbi.nlm.nih.gov/pubmed/11693008?tool=bestpractice.com
Hard objects that can be reached, including wheelchairs, need soft padding.[53]Letts RM, Hobson DA. Special devices as aids in the management of child self-mutilation in the Lesch-Nyhan syndrome. Pediatrics. 1975 Jun;55(6):852-5.
http://www.ncbi.nlm.nih.gov/pubmed/1134885?tool=bestpractice.com
During inpatient admissions, limited to those that are absolutely necessary, restraints should be applied at all times to prevent self-injury, including during sleep. This disease is exempted from the regulations of the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) against continuous and long-term restraints.
Macrocytic anemia
Macrocytic anemia may be found in LND patients.[26]Watts RW, Spellacy E, Gibbs DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 1982;51(201):43-78.
http://www.ncbi.nlm.nih.gov/pubmed/7111674?tool=bestpractice.com
[54]van der Zee SP, Schretlen ED, Monnens LA. Megaloblastic anaemia in the Lesch-Nyhan syndrome. Lancet. 1968 Jun 29;1(7557):1427.
http://www.ncbi.nlm.nih.gov/pubmed/4173010?tool=bestpractice.com
The cause is uncertain, as serum vitamin B12, folate, iron, and thyroid function tests are typically normal, and supplements are usually not effective.[3]Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2001:2537-2570.